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Objectives: The ongoing ASCEND trial of natalizumab utilizes a novel composite 
endpoint, comprised of the Expanded Disability Status Scale (EDSS), Timed 25-Foot 
Walk (T25FW) and 9-Hole Peg Test (9HPT) to assess disability progression in patients 
with secondary-progressive multiple sclerosis (SPMS), due to the limited ability of 
EDSS alone to assess disability progression in this patient population. Given that 
the ASCEND data are not available, data from the IMPACT study was used to assess 
the cost-effectiveness of SPMS treatments in an economic model capturing the 
interrelated changes of these measures for individual patients. This study presents 
the model concept and assesses its external predictability. MethOds: A discrete 
event simulation was developed to predict times to disability progressions on EDSS, 
T25FW, and 9HPTand the occurrence of relapses over time, using four parametric 
(Weibull) functions, each adjusted by a Cox model to ensure that each event time 
was estimated based on patients’ baseline and time-varying factors. Each disability 
scale’s value is updated as events occur. Data from the IMPACT study (n= 436, fol-
lowed for 2 years) was extrapolated for longer term. Published data on EDSS from the 
University of British Columbia (UBC) MS database were used for long-term external 
validations. Results: The model closely replicated all four endpoints as observed 
in the IMPACT study at two years. The predicted times for 25% of patients to reach 
EDSS 8 were consistent with those from the UBC data, with 13.4 (model) vs. 14.8 
(UBC) years from EDSS 3.5–4.5, and 8.7 vs. 8.6 years from EDSS 6.0. The distributions 
of T25FW and 9HPT by EDSS level predicted at 10 years were consistent with those 
observed from the IMPACT study. cOnclusiOns: This SPMS model reliably pre-
dicts short- and long-term disability levels, and can serve as the basis for economic 
evaluations of treatments for SPMS.
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Objectives: In a budget impact analysis (BIA), the population is supposed to 
include all patients eligible for the new intervention during the time span of deci-
sion: new incident cases and patients leaving due to death, cure, migration or other 
reasons, must be captured. Additionally, temporal changes in the actual number of 
individuals receiving the intervention must be quantified. While most of the guide-
lines for BIA emphasize this population dynamics aspect, recommendations on how 
to technically implement it are lacking. We introduce a method for implementing 
population dynamics in a chronic disease with multiple disease subtypes using 
object-oriented programming (OOP), and demonstrate its application in model-
ling health and budget impact of a treatment strategy for ankylosing spondylitis 
(AS). MethOds: A generic hierarchical patient class structure was developed to 
systematically organize the prevalent population and incident cohorts of patients 
with different disease subtypes. Using the concepts of inheritance and polymor-
phism in OOP, we formulated algorithms to efficiently compute health measures 
and resource utilization of individual patients in different classes, and to perform 
probabilistic sensitivity analysis. In the case study, a dynamic population model was 
developed to predict the burden of AS in the Dutch society over a 20-year period from 
January 1, 2015 onwards when a sequential treatment strategy including tumour 
necrosis factor antagonists was applied. Data for model parameterization were 
obtained from the Outcomes Assessment of AS International Study (OASIS) and 
literature. Results: The case study demonstrated that our dynamic population 
modelling method offers an efficient approach to quantify annual as well as total 
health and costs for different decision time spans. Annual direct costs incurred 
by the AS patients in the Dutch Society would range from 471 to 496 million Euros 
between 2015-2035. cOnclusiOns: Our method for implementation of population 
dynamics is efficient and generic, so it can be applied to other chronic diseases.
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Objectives: To evaluate the economic impact of a recently approved therapy, 
delayed-release dimethylfumarate (DMF; also known as gastro-resistant DMF), on 
the overall management costs of relapsing-remitting multiple sclerosis (RRMS) in 
Italy. MethOds: A budget impact model, adopting the perspective of the Italian 
National Healthcare Service (NHS), was used to compare healthcare costs of two 
different treatment scenarios: a) base-case, in which DMF is not reimbursed/funded 
by the NHS, vs. b) reimbursement-case, in which DMF is reimbursed and funded by 
the NHS. Healthcare costs sustained by the Italian NHS to manage the RRMS popu-
lation (drug treatment, administration, therapy and disease monitoring, relapse 
management, treatment-related adverse events) have been calculated over 3 years 
and compared for the two scenarios. Impact of relapses for the disease modify-
ing therapies (DMTs) included in the analysis was estimated using results from 
published literature. RRMS population treated with DMTs was estimated using 
Italian prevalence and incidence data. According to these estimates, the number 
of treated patients amounted to 35,100 at Year 1, 36,800 at Year 2, and 38,700 at Year 
3. Results: According to current price and reimbursement conditions established 
by the Italian NHS, it was estimated that the introduction of DMF (reimbursement-
case) would determine a decrease of the budget impact, if compared with the 
base-case (non-reimbursement case). Over three years, the budget impact would 
be € 1,388,640,000 in the base-case and € 1,359,800,000 in the reimbursement-case 
(-€ 28,840,000; -2.1% relative budget variation). The main drivers for cost-saving were 
pharmacological treatment costs and reduced burden of relapses (corresponding 
to about 1,500 avoided relapses). cOnclusiOns: At the current reimbursement 
increased risk of secondhand smoking on morbidity and mortality. The impact of 
secondhand smoking was included in a previously published Markov model called the 
BENESCO model to estimate the economic burden in Korea. Transition probabilities 
and costs were acquired from Korean public data. The time horizon was lifetime and 
assumed 5% discount rate for costs. The estimated cost was compared with published 
estimates to establish external validity of the model. Results: 13.7% of women (≥ 
19 years old) and 30.7% of children (13-18 years old) from general population were 
exposed to secondhand smoke in household. Relative risks of secondhand smoking 
related diseases were lung cancer 1.9(95% CI 1.0-3.5), coronary heart disease 1.27(95% 
CI: 1.19-1.36), stroke 1.25(95% CI: 1.12-1.38) in women married for smoking husbands. 
The odd of Asthma onset was 1.32 times higher in children whose father smokes. The 
estimated costs were increased by 10 to 50%, compared with the model without the 
impact of secondhand smoking. cOnclusiOns: Cigarette smoking and exposure 
to secondhand smoke is associated with significant economic burden. Policymakers 
should be advised that tobacco control should be aimed not just smokers, but those 
who are vulnerable to secondhand smoking, especially women and children lived 
with smokers.
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Objectives: UKPDS 82 provided updated and new event equations for use in type 
2 diabetes mellitus (T2DM) that include new risk factor (RF) predictors. These new 
RFs do not routinely get reported in clinical studies; consequently, the objective 
of this study research was to report plausible baseline RF values and their time-
dependent trajectories and quantify their impact upon predicted complication 
rates. MethOds: Availability of baseline and time-dependent RF data was assessed 
using a pragmatic literature review. Univariate sensitivity analysis of the UKPDS 82 
equations (over a 40-year horizon ) was undertaken to assess the impact of low-
density lipoprotein [LDL]; microalbuminuria (MA); heart rate (HR); white blood cell 
count (WBC): haemoglobin (Hb) and estimated glomerular filtration rate (eGFR) on 
predicted diabetes complications per 1,000 patients, using UKPDS baseline values 
(varied within the 95% central range). Results: The review identified 32 studies 
reporting baseline RF values typically consistent with UKPDS (review versus UKPDS): 
LDL (2.6-3.8 versus 3.49mmol/l); MA (11-45% versus 6.5%); HR (67-72 versus 72bpm); 
WBC (5.7-7.9 versus 6.6x106/ml); Hb (12.4-14 versus 14.5g/dl); the exception was 
eGFR where baseline values (33-101 versus 77.5ml/min/1.73m2) and decline (0.3-
5.2ml/min/1.73m2/year) varied widely. Utilising UKPDS 82 baseline values resulted 
in 877 macrovascular and 133 microvascular events predicted with 691 to 1,181 and 
116 to 182, respectively, predicted in sensitivity analyses; drivers of risk were LDL 
and eGFR. Varying eGFR decline between 0.3 to 5.2ml/min/1.73m2/year resulted 
in annual event rates for end stage renal disease (ESRD) between 0.021 to 1.251%; 
holding eGFR constant over time resulted in ESRD annual event rate of 0.020%, 
significantly lower than observed in UKPDS (0.13%). cOnclusiOns: Appropriate 
specification of RF is important in diabetes modelling. This study suggests that 
the UKPDS profile is generally consistent with other identified T2DM populations. 
Modelling a decline in eGFR improved the predictive accuracy of ESRD incidence.
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Objectives: Erlotinib, a tyrosine-kinase inhibitor, has been recommended for use in 
non-small cell lung cancer patients harbouring an EGFR mutation. The present study 
is retrospective in nature; using published clinical trial data for erlotinib, it demon-
strates how an analysis of Phase II data could be used to identify what data Phase III 
studies should focus on collecting. MethOds: Phase II data were identified through 
a targeted literature search and used to determine the cost-effectiveness of erlotinib, 
utilising a simple Markov model framework. Data from the literature were mapped 
to model inputs using statistical data analysis methods. Value of Information (VOI) 
analysis tools, such as Expected Value of Perfect Information (EVPI) and Expected 
Value of Partial Perfect Information (EVPPI) were used to identify those uncertain 
parameters having research value in a prospective Phase III program. These findings 
helped to optimise the design of a hypothetical Phase III trial for erlotinib that could 
collect data that is most relevant for reimbursement decision-making. Results: 
At a cost-effectiveness threshold of £30,000 per quality-adjusted life year (QALY) 
gained, the population EVPI was £3,269,358, indicating that further research is valu-
able. The EVPPI identified the log hazards of erlotinib (intervention) and gefitinib 
(comparator) for progression-free survival and overall survival as the parameters for 
which uncertainty was the most valuable. The value of the uncertainty associated 
with other parameters, such as utilities and costs, was much lower. Hence, subse-
quent studies should focus on providing further information on efficacy parameters 
rather than on utilities and costs. cOnclusiOns: Undertaking VOI analysis on data 
collected at Phase II can help ensure that Phase III trials are designed efficiently, in 
turn ensuring that uncertainty in future decision-making is minimised. This model 
demonstrated the VOI from a public policy perspective. This could be extended to 
other perspectives to ensure greater relevance in different settings.
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respiratory product class. Using a dynamic price development graph, the model 
provides explanations for price changes at re-referencing time-points. The model 
clearly demonstrates that Greece leaving the EU will have a significant impact on 
price and revenue across markets, demonstrating the spill-over caused by interna-
tional referencing. cOnclusiOns: The impact of Grexit goes well beyond Greece, 
directly affecting pharmaceutical price and revenue throughout Europe. PRISM 
can be used to assist manufacturers in developing a comprehensive pricing strat-
egy and facilitate dialog with governments operating within fiscally constrained 
environments. The model can also be used to test future scenarios as emerging 
markets are increasingly adopting reference pricing.
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Objectives: This study sought to identify disease- and patient-specific charac-
teristics impacting on disease progression and outcomes, and to determine key 
attributes to be used in developing a conceptual model of multiple myeloma 
(MM). MethOds: English language studies reporting MM attributes and their 
association with disease progression and outcomes were identified from Embase 
and Medline (2004–2014) and congress abstracts (2012–2014) in a systematic litera-
ture review (SLR). A second SLR of treatment guidelines, economic models, health 
technology reports and studies on the burden of MM was also used. An attribute 
was defined as a metric or characteristic of MM that plays a potential role in the 
disease process. These attributes can be explanatory (e.g. patient characteristics) or 
dependant (e.g. survival). Results: From both SLRs, 95 MM attributes were identi-
fied. These were grouped into disease characteristics (e.g. light chains, International 
Staging System [ISS] stage, bone marrow plasma cells, extramedullary disease, 
karyotypic abnormalities), genetic factors [e.g. t(4;14), del(13p), del(17p), hypodip-
loidy, hyperdiploidy], patient characteristics (e.g. age, serum lactate dehydrogenase, 
gender, Eastern Cooperative Oncology Group performance status, comorbidities), 
outcomes (e.g. overall survival), quality of life and symptoms (e.g. pain, fatigue, 
weakness, bone fractures, infection). Attributes were then categorised as explana-
tory or dependent variables. Age, serum lactate dehydrogenase, light chains and 
M protein were among the most common explanatory variables in the literature. 
The most commonly reported dependent variable was overall survival, followed by 
quality of life. None of the studies presented a comprehensive set of determinants of 
disease progression and outcomes. cOnclusiOns: MM is a heterogeneous condi-
tion and it is not yet clear which attributes play a key role in determining disease 
progression and survival. The next step in developing the conceptual model for MM 
is to ask physicians to validate the potential attributes identified and to clarify the 
relationships between validated attributes.
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Objectives: Treatment switching commonly occurs in the pivotal HTA evidence 
for advanced or metastatic cancer treatments submitted to reimbursement agen-
cies. Simple approaches, such as Intention-to-treat (ITT) analysis, have typically 
been applied to data with treatment switching, despite simulation studies showing 
these to drastically underestimate the underlying treatment effect. Therefore, before 
these studies are included in secondary analyses, the data must be re-analysed 
appropriately. When only summary data are available, individual patient level data 
can be reconstructed using a simulation approach. Given patients switch on disease 
progression, their progression time is assumed equivalent to their switch time. 
Simulating this effectively requires an illness-death modelling framework; the pro-
cess of which is the aim of this research. MethOds: An example was used, where 
Kaplan-Meier curves for all three transition rates were available. The coordinates 
were extracted digitally from these scanned survival curves, and used to model 
the times for each transition. Many datasets were created, where the times for the 
transitions were simulated from the respective models. ITT summary statistics 
were calculated for each dataset; then averaged over. Examples with increasingly 
less information on which to estimate the transition rates were also systematically 
investigated. Results: When information on transition rates is available, the pro-
cess is easy to implement; giving data that are, on average, broadly representative 
of the original dataset with median survival times and overall survival hazard ratio 
differing by less than 10% and 0.05 respectively. As the information becomes more 
limited, the process requires additional assumptions, and ultimately may not be 
feasible. cOnclusiOns: Using an illness-death modelling framework to simulate 
individual patient level data is affected by the information available to the analyst. 
However, this approach is important, when addressing treatment switching where 
only summary data are available, as the relationship between time to progression 
and overall survival is modelled correctly.
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Objectives: Over the past five years, the prevalence and incidence of HIV in Russian 
Federation have increased dramatically. The application of global Markov models, 
and cost conditions applied in Italy, the use of DMF is economically sustainable 
for the NHS. Plausibly, the introduction and usage of this new therapy in RRMS 
patients will ensure clinical benefits for patients without resulting in additional 
costs for the NHS.
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Objectives: Ministry of Health of Russian Federation announced the support of 
innovative development of pharmaceutical industry. In accordance with these plans, 
we aimed to develop a methodology for quantitative assessment of therapeutic 
value of innovative medical technologies in a multi-criteria decision analysis man-
ner. MethOds: The questionnaire was developed during pilot survey (10 experts). 
Then 248 respondents assessed criteria significance (weights) of 14 features of an 
innovative drug and 7 features of a relevant disease. Also they estimated scale’s val-
ues. The respondents were medical practitioners and decision makers in healthcare. 
Results of the survey were analyzed using statistical methods. Results: The most 
valuable features are clinical efficacy and clinical safety with the weights of 9.77% 
and 9.08%, respectively. Absence of effective treatment of the disease, mortality and 
influence on quality of life also are among the valuable features with the weights 
of 8.08%, 7.72% and 7.47%, respectively. Minimal weights have new manufacturing 
technique of the drug (0.69%) and new drug formulation (0.03%). cOnclusiOns: 
Significant and non-significant features of an innovative medical technology and 
disease for which it is intended in terms of therapeutic value were identified. We 
plan to optimize set of criteria and scales and then to assess reliability and validity 
of the developed instrument. This methodology being incorporated in the system 
of evaluation of medical technologies and combined with other methods of analy-
ses will help decision-making regarding innovative drugs in Russia become more 
harmonious and transparent.
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Objectives: The cost-effectiveness of screening interventions is typically exam-
ined using simulation models. These permit comparisons of multiple screening 
strategies. Cost-effectiveness estimates from such models depend, in part, on what 
alternatives analysts choose to compare and how the simulation results are inter-
preted. Sometimes the comparisons and interpretations made are inappropriate, 
which can obscure evidence and lead to the wrong policy conclusions. The objective 
of this study is to explain eight simple steps that analysts can take to avoid these 
problems. MethOds: We use examples from the literature to show how these 
problems can arise and to explain how they can be avoided. The examples chosen 
are from a recent systematic review of the cost-effectiveness of cervical screen-
ing. Results: The eight recommendations are: (i) report costs and effects, rather 
than just incremental cost-effectiveness ratios (ICERs); (ii) present a cost-effec-
tiveness plane; (iii) report cost and effects for all strategies, not just those on the 
efficient frontier; (iv) do not report ICERs for dominated strategies; (v) report costs 
and effects to sufficient significant figures; (vi) include all simulated strategies in 
the basecase analysis; (vii) do not report ICERs for strategies for which it is antici-
pated the inclusion of additional strategies would lead to significant changes in 
the estimated ratio; (viii) when there are multiple factors to vary in a screening 
programme, only vary these factors one at a time when creating alternative strat-
egies. cOnclusiOns: The cost-effectiveness estimates from simulation models 
are particularly dependent on the choices taken by analysts regarding both the 
modelling of alternatives and the interpretation of the cost and effects estimates. 
Although the analytical flaws informing our recommendations might seem obvious, 
they occur with surprising frequency in the literature. The simple eight-item list 
presented here will support better use of screening models in identifying optimal 
policy choices.
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Objectives: The possibility of Greece leaving the European Union (Grexit) is 
well-publicized, but its impact on the pharmaceutical industry has not been fully 
determined. Majority of established markets use pricing rules that reference 
products both across (international reference pricing; IRP) and within (thera-
peutic reference pricing; TRP) country-lines. IRP and TRP are used as effective 
measures to control price of pharmaceutical products. There is a growing need 
to understand how Grexit will impact these mechanisms through direct or indi-
rect means. MethOds: Navigant’s Price and Revenue Impact Simulation Model 
(PRISM), which simulates the impact of IRP and TRP, as well as parallel trade and 
generic entry, was used to quantitatively assess the impact on drug prices across 
50 markets in the EU, North America, Latam, MENA-CIS and Asia. Respiratory 
products were analysed as a class to prevent a biased analysis towards particular 
pharmaceutical companies. Two potential scenarios were analysed with respect 
to Grexit: Markets referencing Greece switch referencing to Slovakia, a replace-
ment low-priced Euro currency Mandatory price cut in Greece resulting from a 
currency shift to the Greek Drachma Results: Outputs of the analysis include 
impact on price, revenue and net present value as well as parallel trade of the 
